198 related articles for article (PubMed ID: 34552007)
21. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
Luszczek W; Cheriyath V; Mekhail TM; Borden EC
Mol Cancer Ther; 2010 Aug; 9(8):2309-21. PubMed ID: 20682643
[TBL] [Abstract][Full Text] [Related]
22. PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.
Yin L; Liu Y; Peng Y; Peng Y; Yu X; Gao Y; Yuan B; Zhu Q; Cao T; He L; Gong Z; Sun L; Fan X; Li X
J Exp Clin Cancer Res; 2018 Jul; 37(1):153. PubMed ID: 30012171
[TBL] [Abstract][Full Text] [Related]
23. Novel therapeutic approaches in chondrosarcoma.
Polychronidou G; Karavasilis V; Pollack SM; Huang PH; Lee A; Jones RL
Future Oncol; 2017 Mar; 13(7):637-648. PubMed ID: 28133974
[TBL] [Abstract][Full Text] [Related]
24. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
Ghayad SE; Rammal G; Sarkis O; Basma H; Ghamloush F; Fahs A; Karam M; Harajli M; Rabeh W; Mouawad JE; Zalzali H; Saab R
Cancer Biol Ther; 2019; 20(3):272-283. PubMed ID: 30307360
[TBL] [Abstract][Full Text] [Related]
25. Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells.
Zhang S; Zhan L; Li X; Yang Z; Luo Y; Zhao H
Int J Biol Sci; 2021; 17(13):3381-3400. PubMed ID: 34512154
[TBL] [Abstract][Full Text] [Related]
26. A Succinate Ether Derivative of Tocotrienol Enhances Dickkopf-1 Gene Expression through Epigenetic Alterations in Malignant Mesothelioma Cells.
Sato A; Ueno H; Fusegi M; Kaneko S; Kohno K; Virgona N; Ando A; Sekine Y; Yano T
Pharmacology; 2018; 102(1-2):26-36. PubMed ID: 29763912
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases.
Vendetti FP; Rudin CM
Expert Opin Biol Ther; 2013 Sep; 13(9):1273-85. PubMed ID: 23859704
[TBL] [Abstract][Full Text] [Related]
28. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
Gozzini A; Santini V
Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic regulation of gene expression as an anticancer drug target.
Ferguson LR; Tatham AL; Lin Z; Denny WA
Curr Cancer Drug Targets; 2011 Feb; 11(2):199-212. PubMed ID: 21158714
[TBL] [Abstract][Full Text] [Related]
30. The Effect of 5-Aza-2'-Deoxycytidine in Combination to and in Comparison with Vorinostat on DNA Methyltransferases, Histone Deacetylase 1, Glutathione S-Transferase 1 and Suppressor of Cytokine Signaling 1 Genes Expression, Cell Growth Inhibition and Apoptotic Induction in Hepatocellular LCL-PI 11 Cell Line.
Sanaei M; Kavoosi F; Esmi Z
Int J Hematol Oncol Stem Cell Res; 2020 Jan; 14(1):45-55. PubMed ID: 32337014
[No Abstract] [Full Text] [Related]
31. Epigenetic silencing of apoptosis-inducing gene expression can be efficiently overcome by combined SAHA and TRAIL treatment in uterine sarcoma cells.
Fröhlich LF; Mrakovcic M; Smole C; Lahiri P; Zatloukal K
PLoS One; 2014; 9(3):e91558. PubMed ID: 24618889
[TBL] [Abstract][Full Text] [Related]
32. Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation.
Chistiakov DA; Orekhov AN; Bobryshev YV
Int J Cardiol; 2017 Jan; 227():66-82. PubMed ID: 27852009
[TBL] [Abstract][Full Text] [Related]
33. Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells.
Yuan J; Llamas Luceño N; Sander B; Golas MM
Cell Oncol (Dordr); 2017 Jun; 40(3):263-279. PubMed ID: 28429280
[TBL] [Abstract][Full Text] [Related]
34. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
[TBL] [Abstract][Full Text] [Related]
35. Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer.
Chun SG; Zhou W; Yee NS
Cancer Biol Ther; 2009 Jul; 8(14):1328-39. PubMed ID: 19421011
[TBL] [Abstract][Full Text] [Related]
36. Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
Teixeira SR; Abreu CM; Parkes L; Davies J; Yao S; Sawhney MA; Margarit L; Gonzalez D; Pinto IM; Francis LW; Conlan RS
Biosens Bioelectron; 2019 Sep; 141():111386. PubMed ID: 31220725
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic-based therapies in cancer: progress to date.
Song SH; Han SW; Bang YJ
Drugs; 2011 Dec; 71(18):2391-403. PubMed ID: 22141383
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors repress chondrosarcoma cell proliferation.
Zhu J; Gu J; Ma J; Xu Z; Tao H
J BUON; 2015; 20(1):269-74. PubMed ID: 25778327
[TBL] [Abstract][Full Text] [Related]
39. Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo.
Wei Y; Zhou F; Lin Z; Shi L; Huang A; Liu T; Yu D; Wu G
Anticancer Drugs; 2018 Mar; 29(3):262-270. PubMed ID: 29356692
[TBL] [Abstract][Full Text] [Related]
40. Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region.
Liang Y; Zeng J; Jelicks L; Ma S; Liu J; Mei J; Perez-Soler R; Zou Y
Curr Cancer Drug Targets; 2017; 17(2):169-176. PubMed ID: 27029827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
